Metabolon, Inc. has announced that results from a study of its Quantose IGT™ test were recently published in the Journal of Diabetes Science and Technology. The study provided data that supports the clinical validity of the test for assessing impaired glucose tolerance (IGT), a state of prediabetes.
According to the American Diabetes Association, people with IGT have a relatively high risk of developing type 2 diabetes and cardiovascular disease. Recognizing IGT is important in the prevention and management of these serious conditions.
“This study verified that the Quantose IGT test accurately reflects IGT, which may provide the opportunity for earlier clinical intervention that could help curb the epidemic of type 2 diabetes,” stated Eric Button, Senior Vice President of Diagnostics at Metabolon. “We look forward to bringing this new test to the market in the coming months.”
Quantose IGT is designed to easily identify IGT using a single, fasted blood draw. This simple test is a convenient surrogate for the oral glucose tolerance test (OGTT), the currently accepted clinical practice for measuring IGT.
Although the OGTT can effectively measure IGT, patients must fast prior to having the test, and after establishing a fasting glucose level by means of a blood draw, the patient must then drink a glucose-rich beverage and undergo multiple blood draws over the course of about two hours. Because it is time consuming and can cause patients to feel nauseated, sweaty or lightheaded, the OGTT is unpopular with primary care physicians and patients.
Metabolon’s metabolomic profiling technology identified a number of metabolites whose fasting levels are associated with dysglycemia and type 2 diabetes. These metabolites are the basis of an alternative test for IGT.
Metabolon developed Quantose IGT using fasting plasma samples taken just prior to an OGTT from 1,623 nondiabetic subjects from two different cohorts: 955 from the Relationship between Insulin Sensitivity and Cardiovascular Disease Study (RISC Study; 11.7% IGT) and 668 subjects from the Diabetes Mellitus and Vascular Health Initiative (DMVhi) cohort from the DEXLIFE project (11.8% IGT).